Bempegaldesleukin Terminated Phase 3 Trials for Metastatic Renal Cell Carcinoma ( mRCC) / Renal Cell Carcinoma (RCC) Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Terminated | Treatment | 3 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) |